pimozide has been researched along with Acute Myelogenous Leukemia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukutake, S; Kurosu, T; Miura, O; Nagao, T; Nogami, A; Okada, K; Oshikawa, G; Umezawa, Y | 1 |
1 other study(ies) available for pimozide and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Carrier Proteins; Caspase 9; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4G; Eukaryotic Initiation Factors; fms-Like Tyrosine Kinase 3; Heterocyclic Compounds, 3-Ring; Humans; Indazoles; Leukemia, Myeloid, Acute; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Pimozide; Proto-Oncogene Proteins c-akt; STAT5 Transcription Factor; Sulfonamides; TOR Serine-Threonine Kinases | 2015 |